Suppr超能文献

儿童髓母细胞瘤的风险适应性化疗。

Risk-adapted chemotherapy in childhood medulloblastoma.

机构信息

Department of Pediatric Oncology, Hacettepe University, Institute of Oncology, 06100 Ankara, Turkey.

出版信息

Expert Rev Anticancer Ther. 2011 May;11(5):771-80. doi: 10.1586/era.10.222.

Abstract

Medulloblastoma is the most common malignant brain tumor in children. The treatment strategy in this tumor mainly includes surgery and radiotherapy, but chemotherapy has been successfully applied in medulloblastoma. The survival rates have improved over the last decade with chemotherapy. The most important prognostic factors were the amount and the extent of metastases, surgery and age. Risk factors have been defined in recent years, but chemotherapy has not been planned according to these defined risk factors on a worldwide basis. The aim of this article was to examine the use of chemotherapy in childhood medulloblastoma according to risk group. A secondary aim was to examine high-dose chemotherapy with autologous stem cell transplantation and the treatment of infant medulloblastoma.

摘要

髓母细胞瘤是儿童中最常见的恶性脑肿瘤。该肿瘤的治疗策略主要包括手术和放疗,但化疗已成功应用于髓母细胞瘤。过去十年,随着化疗的应用,生存率得到了提高。最重要的预后因素是转移的数量和范围、手术和年龄。近年来已确定了风险因素,但化疗尚未根据这些全球定义的风险因素进行规划。本文的目的是根据风险组检查儿童髓母细胞瘤中化疗的应用。次要目的是检查大剂量化疗联合自体造血干细胞移植和婴儿髓母细胞瘤的治疗。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验